USFDA inspections back in full swing for Pharma Companies

USFDA plant inspections seem to be coming back strongly after a two-year hiatus, going by the just-concluded inspection at Zydus Lifesciences on March 10 and a warning letter to Aurobindo earlier this year, in mid-January.

USFDA officials commented in February 2022 that USFDA is keen on restarting pharma companies inspections, including surprise inspections in India.

USFDA could be set for a busy year in India as the backlog of redressals from previous inspections and pending applications for plants and products become pressing.

Earlier, the total number of USFDA plant audits for drug quality assurance in India peaked in 2019 at 239.

Another 80 inspections were completed in January-March 2020 prior to Covid and slid to 5 inspections in 2021.

The surge in audit inspections could be periodic or could also be linked to evolving standards in manufacturing.

Related Posts

  • Pharma
  • June 17, 2025
  • 113 views
Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…

  • Pharma
  • June 17, 2025
  • 107 views
Zydus Healthcare appoints Swati Dalal MD

Zydus Lifesciences Ltd on Monday announced the appointment of Swati Dalal as an additional director and Managing Director of its wholly-owned arm Zydus Healthcare Ltd. The board of Zydus Healthcare…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Zydus Healthcare appoints Swati Dalal MD

Zydus Healthcare appoints Swati Dalal MD

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

Natco API plant gets one observation from FDA

Natco API plant gets one observation from FDA